Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium
- 8 January 2021
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (8) , 2969-2975
Abstract
Purpose To investigate the natural history and follow-up after kidney tumor treatment of Von Hippel-Lindau (VHL) patients. Materials and methods A multi-institutional European consortium of patients with VHL syndrome included 96 non-metastatic patients treated at 9 urological departments (1987–2018). Descriptive and survival analyses were performed. Results and limitations Median age at VHL diagnosis was 34 years (IQR 25–43). Two patients (2.1%) showed only renal manifestations at VHL diagnosis. Concomitant involvement of Central Nervous System (CNS) vs. pancreas vs. eyes vs. adrenal gland vs. others were present in 60.4 vs. 68.7 vs. 30.2 vs. 15.6 vs. 15.6% of patients, respectively. 45% of patients had both CNS and pancreatic diseases alongside kidney. The median interval between VHL diagnosis and renal cancer treatment resulted 79 months (IQR 0–132), and median index tumor size leading to treatment was 35.5 mm (IQR 28–60). Of resected malignant tumours, 73% were low grade. Of high-grade tumors, 61.1% were large > 4 cm. With a median follow-up of 8 years, clinical renal progression rate was 11.7% and 29.3% at 5 and 10 years, respectively. Overall mortality was 4% and 7.5% at 5 and 10 years, respectively. During the follow-up, 50% of patients did not receive a second active renal treatment. Finally, 25.3% of patients had CKD at last follow-up. Conclusions Mean period between VHL diagnosis and renal cancer detection is roughly three years, with significant variability. Although, most renal tumors are small low-grade, clinical progression and mortality are not negligible. Moreover, kidney function represents a key issue in VHL patients.Keywords
This publication has 24 references indexed in Scilit:
- Renal cancerThe Lancet, 2016
- HIF Hydroxylase Pathways in Cardiovascular Physiology and MedicineCirculation Research, 2015
- Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass BiopsyJournal of Urology, 2015
- Pilot trial of sunitinib therapy in patients with von Hippel–Lindau diseaseAnnals of Oncology, 2011
- von Hippel–Lindau disease: A clinical and scientific reviewEuropean Journal of Human Genetics, 2011
- von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafishDisease Models & Mechanisms, 2010
- Pseudohypoxic Pathways in Renal Cell CarcinomaClinical Cancer Research, 2007
- THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASEJournal of Urology, 2004
- PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCEJournal of Urology, 2001
- PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMAJournal of Urology, 1998